1-deoxy analogs of 1,25-dihydroxyvitamin D3 compounds
This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
1. A compound having Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein each independently is a single bond or a double bond;
n is 0, 1 or 2;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo;
with the proviso that when n is 0, then R 7 is O; and
with the proviso that when each is a single bond, n is 1, R 1 is OH, R 2 and R 3 together form ═CH 2 , R 4 is C 1 alkyl, R 5 and R 6 are each H, and R 8 is methyl, then R 7 is selected from the group consisting of NH, N(C 1-6 alkyl), and NC(O)R 9 .
2. The compound of claim 1 , wherein
n is 0 or 1;
R 1 is OH or halo;
R 2 and R 3 are either both H or together form ═CH 2 ;
R 4 is C 1-4 alkyl;
R 5 and R 6 are each independently H, halo, or C 1-2 alkyl, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is selected from the group consisting of 0, NH, and N(C 1-6 alkyl); and
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , and halo.
3. The compound of claim 2 , wherein
R 1 is OH or F;
R 2 and R 3 together form ═CH 2 ;
R 4 is CH 3 ;
R 5 and R 6 are each independently H, halo, or CH 3 , with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is O or NH; and
R 8 is selected from the group consisting of C 1-4 alkyl, aryl and heteroaryl, wherein each of aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , and halo.
4. The compound of claim 3 , wherein
R 1 is OH; and,
R 5 and R 6 are each independently H, CH 3 , Cl, or F, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent; and
R 8 is selected from the group consisting of C 1-4 alkyl and aryl, wherein aryl is either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , and halo.
5. The compound of claim 4 , selected from the group consisting of:
6. The compound of claim 1 having a relative stereochemistry as shown below:
7. The compound of claim 6 selected from the group consisting of:
8. A pharmaceutical composition comprising an admixture of a pharmaceutically-acceptable excipient and a compound:
(i) having Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein each independently is a single bond or a double bond;
n is 0, 1 or 2;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo;
with the proviso that when n is 0, then R 7 is O; and
with the proviso that when each is a single bond, n is 1, R 1 is OH, R 2 and R 3 together form ═CH 2 , R 4 is C 1 alkyl, R 5 and R 6 are each H, and R 8 is methyl, then R 7 is selected from the group consisting of NH, N(C 1-6 alkyl), and NC(O)R 9 ; or
having Formula III, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein is a single bond or a double bond;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and,
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo.
9. A method for treating diseases which benefit from an increase in the levels of 1α,25-dihydroxyvitamin D 3 , or for treating diseases which benefit from an inhibition of the catabolism of 1α,25-dihydroxyvitamin D 3 , or for treating one or more diseases selected from the group consisting of breast cancer, lung cancer, prostate cancer, colon cancer, colorectal cancer, kidney cancer, head and neck cancer, pancreatic cancer, skin cancer, Kaposi's sarcoma, leukemia, and psoriasis, or for inhibiting CYP24 activity in a cell or animal, or for increasing the levels of 1α,25-dihydroxyvitamin D 3 in a cell or animal, or for inhibiting the catabolism of 1α,25-dihydroxyvitamin D 3 in a cell or animal, comprising administering to a cell or animal in need thereof an effective amount of a compound:
(i) having Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein each independently is a single bond or a double bond;
n is 0, 1 or 2;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo;
with the proviso that when n is 0, then R 7 is O; and
with the proviso that when each is a single bond, n is 1, R 1 is OH, R 2 and R 3 together form ═CH 2 , R 4 is C 1 alkyl, R 5 and R 6 are each H, and R 8 is methyl, then R 7 is selected from the group consisting of NH, N(C 1-6 alkyl), and NC(O)R 9 ; or
having Formula III, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein is a single bond or a double bond;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and,
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo.
10. A method of increasing the efficacy of a vitamin D receptor agonist comprising co-administering an effective amount of the vitamin D receptor agonist and a compound having Formula I, or a pharmaceutically acceptable salt, solvate, or hydrate thereof:
wherein each independently is a single bond or a double bond;
n is 0, 1 or 2;
R 1 is selected from the group consisting of OH, OC 1-6 alkyl, and halo;
R 2 and R 3 are each independently H or halo, or together form ═CH 2 ;
R 4 is C 1-6 alkyl;
R 5 and R 6 are each independently H, halo, C 1-4 alkyl, or can be taken, together with the carbon atom to which they are bound, to form a C 3-6 cycloalkyl ring, with the proviso that when between carbon-23 and carbon-24 is a double bond, then R 5 is absent;
R 7 is selected from the group consisting of O, NH, N(C 1-6 alkyl), and NC(O)R 9 ;
R 8 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo, OH, OCF 3 , SH, SC 1-4 alkyl, NH 2 , NHC 1-4 alkyl, N(C 1-4 alkyl)(C 1-4 alkyl), and CN; and
R 9 is selected from the group consisting of C 1-6 alkyl, C 3-6 cycloalkyl, aryl-C 1-4 alkyl, aryl and heteroaryl, wherein each of C 1-6 alkyl, C 3-6 cycloalkyl, aryl and heteroaryl are either unsubstituted or substituted with 1 to 5 substituents independently selected from the group consisting of C 1-4 alkyl, OC 1-4 alkyl, CF 3 , NO 2 , halo;
with the proviso that when n is 0, then R 7 is O; and
with the proviso that when each is a single bond, n is 1, R 1 is OH, R 2 and R 3 together form ═CH 2 , R 4 is C 1 alkyl, R 5 and R 6 are each H, and R 8 is methyl, then R 7 is selected from the group consisting of NH, N(C 1-6 alkyl), and NC(O)R 9 .
11. The compound of claim 1 , wherein:
R 7 is O;
with the proviso that when each is a single bond, R 2 and R 3 together form ═CH 2 , R 4 is C 1 alkyl, R 5 and R 6 are each H, and R 8 is methyl, then n is 0 or 2.
12. The method of claim 9 , wherein the method comprises treating a disease which benefits from an increase in the levels of 1α,25-dihydroxyvitamin D 3 .
13. The method of claim 9 , wherein the method comprises treating a disease which benefits from an inhibition of the catabolism of 1α,25-dihydroxyvitamin D 3 .
14. The method of claim 9 , wherein the method comprises treating one or more diseases selected from the group consisting of breast cancer, lung cancer, prostate cancer, colon cancer, colorectal cancer, kidney cancer, head and neck cancer, pancreatic cancer, skin cancer, Kaposi's sarcoma, leukemia, and psoriasis.
15. The method of claim 9 , wherein the method comprises inhibiting CYP24 activity in a cell or animal.
16. The method of claim 9 , wherein the method comprises increasing the levels of 1α,25-dihydroxyvitamin D 3 in a cell or animal.
17. The method of claim 9 , wherein the method comprises inhibiting the catabolism of 1α,25-dihydroxyvitamin D 3 in a cell or animal.